Key result
Warfarin co-administered with sulfonylureas carries a risk of serious hypoglycemic events that depends on the dose, length of treatment, and the specific sulfonylurea used.
Why the study?
Does the use of warfarin with sulfonylureas increase the risk of serious hypoglycemic events?
Does the use of warfarin with sulfonylureas increase the risk of serious hypoglycemic events?
The text highlights the importance of considering potential interactions between warfarin and sulfonylureas, which can lead to serious hypoglycemic events due to their narrow therapeutic ranges.
Romley and colleagues studied the association between the use of warfarin with common sulfonylureas and the development of serious hypoglycemic events.1 Data on potential interactions are essential because both drugs have a narrow therapeutic range and can also interact with many other drugs.2 3 The pharmacological effect of these drugs …
No takes yet. Share an insight, caveat, or question.
Bosco‐Lévy et al. (2016) studied this question. Warfarin co-administered with sulfonylureas carries a risk of serious hypoglycemic events that depends on the dose, length of treatment, and the specific sulfonylurea used.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: